Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Nanoparticle-based drug delivery systems have found extensive use in delivering oncology
therapeutics; however, some delivery vehicles still exhibit rapid immune clearance, lack of …

Despite the advancements in the treatment of localized pancreatic cancer, several
unresolved issues persist in clinical practice, especially in the neoadjuvant setting. These …

Background The pancreatic index (PI) is a useful preoperative imaging predictor for
pancreatic ductal adenocarcinoma (PDAC). In this retrospective study, we determined the …

Esophageal cancer (EC) is one of the fatal malignant neoplasms worldwide. Neoadjuvant
therapy (NAT) combined with surgery has become the standard treatment for locally …

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Background The aim of this study is to present radiologically designated LAPC found to be
resectable upon surgical exploration and evaluate the outcomes of such resections …

Objectives Differential diagnosis between pancreatic ductal adenocarcinoma (PDAC) and
benign mimickers can be very difficult on small histological samples, such as fine needle …

Pancreatic cancer is a highly aggressive tumor. Due to the lack of characteristic symptoms, it
is usually detected in the advanced stage. Resection of the tumor is possible only in 10-20 …

Endoscopic ultrasound (EUS) has emerged as one of the most valuable tools in current
clinical practice to assess pancreatic tumors, allowing accurate early diagnosis, tumor …